{"product_id":"gstzy-pestle-analysis","title":"Gushengtang Holdings PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how political shifts, economic cycles, social trends, technological advances, legal changes, and environmental pressures are shaping Gushengtang Holdings’ strategic outlook in our concise PESTLE snapshot. These expert insights reveal risks and growth levers critical for investors and planners. Ready-made and actionable, the full PESTLE delivers deeper analysis. Purchase now to download the complete report instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState support for TCM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina embeds TCM in national health strategies (Healthy China 2030 and the 2021–30 TCM plan), enhancing Gushengtang’s brand credibility and public procurement access; the TCM market reached about RMB 1.2 trillion in 2024. Subsidies and inclusion in basic medical insurance and provincial public programs can materially lift demand. Support is selective—priority for standardized, certified practices—forcing compliance investments. Provincial policy and subsidy intensity differ, affecting rollout pacing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare reform dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayment reform and tiered-care policies led by the State Council and NHSA are redirecting patient flows from tertiary hospitals to community clinics and online platforms, increasing competition for Gushengtang across channels. Expansion of outpatient reimbursement pilots for chronic disease and family-doctor services favors compliant private TCM providers that secure NHSA contracting. Price controls and DRG-style diagnosis-related payments implemented in reform pilots have compressed margins for branded treatments. Strategic alignment with local reform pilots improves contracting prospects and patient capture.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic insurance coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInclusion of TCM services and products in NRDL\/PRDL materially affects volumes given China’s public insurance covers over 95% of the population; reimbursement adjustments can provoke demand swings within months, as 2019–20 NRDL negotiations drove average price cuts near 60% for some drugs. Since 2020 HTA guidance, payers require stronger documentation and real-world evidence to retain listings, so close engagement with payers and HTA bodies is a clear differentiator for Gushengtang.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical supply risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeopolitical supply risks threaten herbal inputs and devices via tariffs, logistics bottlenecks and sanctions; over 60% of global active pharmaceutical ingredients are sourced from China and India, concentrating exposure. Cross-border e-commerce rules shape online health-sales channels while localization and domestic partnerships reduce tariff and compliance frictions. Multi-region sourcing and inventory buffers mitigate political shocks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTariffs\/logistics: concentrated APIf supply \u0026gt;60%\u003c\/li\u003e\n\u003cli\u003eCross-border e-commerce: policy-dependent sales channels\u003c\/li\u003e\n\u003cli\u003eLocalization: drives domestic sourcing\/partnerships\u003c\/li\u003e\n\u003cli\u003eMitigation: multi-region sourcing, inventory buffers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLocal government oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLocal clinic licensing, bed quotas and operating permits for Gushengtang are issued at city and provincial levels, with approval timelines typically ranging from 4 to 9 months and significant regional variance in enforcement intensity that directly affects expansion schedules. Health industrial parks (2024-25) commonly offer tax breaks and rent subsidies that can cut upfront capex and operating costs by up to 20%. Proactive compliance programs have been shown to reduce inspection-related downtime by roughly 30–40%, speeding openings and revenue realization.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing level: city\/province\u003c\/li\u003e\n\u003cli\u003eApproval time: 4–9 months\u003c\/li\u003e\n\u003cli\u003eCost reductions in parks: up to 20%\u003c\/li\u003e\n\u003cli\u003eDowntime cut via compliance: ~30–40%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy-backed TCM: \u003cstrong\u003eRMB 1.2T\u003c\/strong\u003e, \u0026gt;95% insured; NRDL, licensing \u0026amp; API risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eState backing (Healthy China 2030, 2021–30 TCM plan) boosts credibility and procurement; TCM market ≈RMB 1.2 trillion (2024) and public insurance covers \u0026gt;95%. NRDL\/HTA drives rapid volume\/price shifts (some NRDL negotiations cut prices ~60%); local licensing (4–9 months) and health-park incentives (capex\/rent cuts up to 20%) shape rollout. API concentration (\u0026gt;60% China\/India) raises geopolitical supply risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTCM market (2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic insurance\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing time\u003c\/td\u003e\n\u003ctd\u003e4–9 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePark incentives\u003c\/td\u003e\n\u003ctd\u003eCapex\/rent −up to 20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI concentration\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNRDL price cuts\u003c\/td\u003e\n\u003ctd\u003eup to 60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise PESTLE evaluation of Gushengtang Holdings, examining Political, Economic, Social, Technological, Environmental and Legal forces with data-backed trends and region\/industry relevance; designed to help executives, investors and strategists identify risks, opportunities and forward-looking scenarios for planning and funding decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Gushengtang Holdings that streamlines external risk assessment and market positioning, easily inserted into presentations or shared across teams for fast alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer health spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising middle-class incomes—China’s middle-income cohort now estimated at ~430 million—are boosting demand for preventive and wellness TCM, with consumer health spending shifting toward lifestyle tonics; during economic slowdowns patients favor reimbursed services and value SKUs, reducing average transaction value. Price elasticity differs: chronic-care essentials show inelastic demand while premium tonics are highly elastic; flexible pricing and tiered packages hedge cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging demographics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina had 200.56 million people aged 65+ in 2023, driving greater demand for chronic condition management where TCM remains widely used. Long-term care trends favor integrative solutions and community-based TCM services. Higher visit frequency among elderly patients helps offset pricing pressure on per-visit margins. Tailored geriatric care pathways can increase patient lifetime value and repeat revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInput cost volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHerbal commodity prices are highly seasonal and climate-sensitive, producing year-on-year swings often reaching 20–30% in harvest-poor years; standardization and contract farming have cut supplier price variance materially by securing yields and quality. Currency moves (RMB fluctuations of several percent vs USD in 2024) raise costs for imported processing equipment and packaging. Dynamic procurement and inventory hedging programs smooth purchase timing and helped stabilize gross-margin pressure. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital channel economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOnline consultations and e-pharmacy can cut CAC 20–40% at scale but incur platform fees of ~10–25%; conversion hinges on trust, speed and reimbursement eligibility, with reimbursed patients converting ~2–3x more often.\u003c\/p\u003e\n\u003cp\u003eOmnichannel integration raises retention ~15–25% and basket size ~20–25%, while data-driven CRM can improve LTV\/CAC by ~25–35% and lower unit variable costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003elower-CAC: 20–40%\u003c\/li\u003e\n\u003cli\u003eplatform-fees: 10–25%\u003c\/li\u003e\n\u003cli\u003ereimbursement lift: 2–3x conversion\u003c\/li\u003e\n\u003cli\u003eretention + basket: +15–25% \/ +20–25%\u003c\/li\u003e\n\u003cli\u003eCRM impact: LTV\/CAC +25–35%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinic expansion and tech buildouts demand sustained capex, with rollout speed tied to credit conditions—China 1‑year LPR held at 3.45% into 2024–25, easing borrowing costs for healthcare projects; equity market sentiment also affects equity raises and M\u0026amp;A timing. Central government policy under the 14th Five‑Year Plan continues to prioritize TCM modernization, enabling targeted grants and pilot funding to defray upfront costs. Gushengtang’s disciplined ROI gates and phased investment approach limit overexpansion risk and preserve liquidity during slower funding windows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapex needs: clinic expansion + tech buildouts\u003c\/li\u003e\n\u003cli\u003eFunding drivers: 1‑yr LPR ~3.45% (2024–25) \u0026amp; equity market health\u003c\/li\u003e\n\u003cli\u003ePolicy support: 14th Five‑Year Plan\/T CM digitization grants\u003c\/li\u003e\n\u003cli\u003eRisk control: phased ROI gates to prevent overexpansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy-backed TCM: \u003cstrong\u003eRMB 1.2T\u003c\/strong\u003e, \u0026gt;95% insured; NRDL, licensing \u0026amp; API risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising middle class (~430m) and 65+ population (200.56m in 2023) lift demand for TCM preventive and geriatric care; premium tonics remain price‑elastic while chronic care is inelastic. Herbal input volatility can swing 20–30% year‑on‑year; 1‑yr LPR ~3.45% (2024–25) eases capex financing. Digital channels cut CAC 20–40% but incur 10–25% platform fees; reimbursement boosts conversion 2–3x.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMiddle class\u003c\/td\u003e\n\u003ctd\u003e~430m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e65+ population (2023)\u003c\/td\u003e\n\u003ctd\u003e200.56m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHerbal price swings\u003c\/td\u003e\n\u003ctd\u003e20–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1‑yr LPR (2024–25)\u003c\/td\u003e\n\u003ctd\u003e3.45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital CAC cut\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform fees\u003c\/td\u003e\n\u003ctd\u003e10–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement lift\u003c\/td\u003e\n\u003ctd\u003e2–3x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eGushengtang Holdings PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Gushengtang Holdings PESTLE Analysis you’ll receive after purchase—fully formatted and ready to use. It contains the full Political, Economic, Social, Technological, Legal, and Environmental assessment as displayed, with no placeholders or teasers. After payment you’ll instantly download this identical, professionally structured file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162695577977,"sku":"gstzy-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/gstzy-pestle-analysis.png?v=1762706986","url":"https:\/\/portersfiveforce.com\/products\/gstzy-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}